All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 16, 2022
Home » Authors » Peter O'Donnell

Peter O'Donnell

Articles

ARTICLES

Chinese biopharmas surge, bulls take over market

April 9, 2019
By Peter O'Donnell
No Comments

HONG KONG – The biotech sector in greater China ended the financial year on a high note. Companies on the Hong Kong Stock Exchange reported better-than-expected results, including seven pre-revenue startups that went public over the last year, adding to the energy in the biotech space.


Read More

China's biopharmas buffeted by conflicting market dynamics

Jan. 16, 2019
By Peter O'Donnell
No Comments

HONG KONG – The late December IPO of Shanghai Junshi Biosciences Co., shortly after the company got a green light for the first made-in-China immunotherapy treatment, delivered a strong close to 2018 for the country's biotech industry. But it did little to mask the huge losses that Chinese pharma stocks suffered through the year.


Read More

Fibrogen, Astrazeneca move roxadustat to first approval in China

Dec. 24, 2018
By Peter O'Donnell
No Comments

In a second first in the same week for China, roxadustat (previously FG-4592), developed by Fibrogen Inc. and partnered in the country with Astrazeneca plc, became the first drug advanced by a global biopharma to receive its initial nod from the National Medical Products Administration (NMPA, formerly the CFDA) before applications were submitted to the FDA and EMA. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) was approved to treat anemia caused by chronic kidney disease (CKD) in patients who are dialysis dependent (DD) and use either hemodialysis or peritoneal dialysis.


Read More

Faster green light for imported drugs ignites international biopharmas' interest in China

Sep. 27, 2018
By Peter O'Donnell
No Comments

HONG KONG – China has seen a busy month of drug approvals, from Lenvima (lenvatinib, Eisai Co. Ltd. and Merck & Co. Inc.) on Sept. 5 to Elunate (fruquintinib, Hutchison China Meditech Ltd.) and Soliris (eculizumab, Alexion Pharmaceuticals Inc.) on Sept. 6. More notably, the three drugs, all accepted under the priority review pathway, were granted marketing approval in about a year.


Read More

Innovent joins CD47 race, chases first home-grown PD-1 approval in China

Sep. 18, 2018
By Peter O'Donnell
No Comments

HONG KONG – Amid renewed interest in CD47 as an immuno-oncology target, Innovent Biologics Inc., of Suzhou, China, has received IND approval in China to start clinical trials of its monoclonal antibody (MAb), IBI-188. To further get ahead in the anti-CD47 race, Innovent will conduct clinical trials on IBI-188 at home and abroad simultaneously.


Read More

Partnering wave still cresting, no splash for M&A transactions

April 13, 2018
By Peter O'Donnell
No Comments

Despite the fact that the industry inked more than 1,000 deals last year, it appears that biopharma companies are not losing their appetite for dealmaking. According to data from BioWorld and Cortellis Deals Intelligence, there were 271 deals signed in the first quarter of 2018, on par with 2017 first quarter transactions. 


Read More

Sandoz and Biocon join forces in global biosimilar deal in immunology, oncology

Jan. 30, 2018
By Peter O'Donnell
No Comments

HONG KONG – Less than two months after picking up a big win with the FDA approval for Mylan NV-partnered Herceptin biosimilar Ogivri (trastuzumab-dkst), India's Biocon Ltd. inked a deal with another leader in biosimilar development, Sandoz Inc., a division of Novartis AG, to develop, manufacture and commercialize multiple products in the areas of immunology and oncology.


Read More

Fosun Pharma's Henlius closing in on China's first biosimilar nod; HLX-01 under review

Nov. 7, 2017
By Peter O'Donnell
No Comments

HONG KONG – With a series of advancements in the area of biosimilar development, China's Shanghai Fosun Pharmaceutical Group Co. Ltd. is getting closer to becoming the first domestic company to market a biosimilar product in China. Fosun Pharma said its subsidiary, Shanghai Henlius Biotech Inc., has received a notice from the CFDA that its first marketing application, for a biosimilar rituximab, is officially under review.


Read More

China's antibiotic firms are struggling with profits

June 28, 2016
By Peter O'Donnell
No Comments

HONG KONG – Stepped up regulations and a curb on the use of antibiotics is hurting the bottom line of antibiotic makers in China. And there is little chance of a change any time soon.


Read More

Gan & Lee planning $227M IPO in China; funds for innovation, global expansion

June 14, 2016
By Peter O'Donnell
No Comments

HONG KONG – Three years after a failed attempt, Chinese insulin maker Gan & Lee Pharmaceuticals Ltd. is looking at China's stock markets.


Read More
View All Articles by Peter O'Donnell

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 13.
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing